DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0065628A1 Johnson Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 2011 0065628A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0065628A1 Johnson et al. (43) Pub. Date: Mar. 17, 2011 (54) MEDICATION COMBINATIONS FOR THE Related U.S. Application Data TREATMENT OF ALCOHOLISMAND DRUG (60) Provisional application No. 60/966,265, filed on Aug. ADDCTION 27, 2007. Publication Classification Inventors: (75) Bankole A. Johnson, (51) Int. Cl. Charlottesville, VA (US); Nassima A63L/485 (2006.01) Ait-Daoud Tiouririne, A6II 3/55 (2006.01) Charlottesville, VA (US); Wendy J. A6II 3/55 (2006.01) Lynch, Charlottesville, VA (US) A 6LX 3/59 (2006.01) A63/496 (2006.01) A6II 3/56 (2006.01) (73) Assignee: UNIVERSITY OF VIRGINA A638/02 (2006.01) PATENT FOUNDATION, A6IP 25/30 (2006.01) Charlottesville, VA (US) A6IP 25/32 (2006.01) A6IP 25/36 (2006.01) A6IP3/04 (2006.01) (21) Appl. No.: 12/675,486 (52) U.S. Cl. .......... 514/1.1: 514/282: 514/215: 514/221; 514/259.41: 514/253.04: 514/253.07: 514/171 (22) PCT Fled: May 20, 2008 (57) ABSTRACT The present invention provides for the use of combinations of (86) PCT NO.: PCT/USO8/64232 drugs to treat addictive disorders. More specifically, the present invention provides compositions and methods for S371 (c)(1), treating disorders using combinations of drugs such as topi (2), (4) Date: Feb. 26, 2010 ramate, ondansetron, and naltrexone. Patent Application Publication Mar. 17, 2011 Sheet 1 of 15 US 2011/0065628A1 3 Mean :::: EEEE EEE D',ay E::::::: :::: B EEEE :::: 1 EEE E::: :: O EEE Plac Ond 1 Ond 4 Ond 16 Plac Ond 1 Ond 4 Ond 16 Start of double blind End of study Placebo (Plac) geton 1 ug/kg b.i.d. n Ondansetron 4 g/kg I Ondansetron 16 ug/kg b.i.d. b.i.d. (Ond 4) (Ond 16) FIG. 1A Patent Application Publication Mar. 17, 2011 Sheet 2 of 15 US 2011/0065628A1 3 i Mean :::: :::: I Drinks 1 EEE :::: Day 2 EEE :::: :::: S ::::: EEE: 1 :::: EEE :::: E :::: EEE O EEE Plac Ond 1 Ond 4 Ond 16 Plac Ond 1 Ond 4 Ond 16 Start of double blind End of study Placebo (Plac) --: 25,Ondansetron 1 ug/kg b.i.d. Ondansetron 4 ug/kg I Ondansetron 16 g/kg b.i.d. b.i.d. (Ond 4) (Ond 16) F.G. 1B Patent Application Publication Mar. 17, 2011 Sheet 3 of 15 US 2011/0065628A1 0.3 Mean 0.2 Log CDT 0.1 Ratio -0.0 -0. -0.2 -0.3 -0.4 Plac Ond 1 Ond 4 Ond 16 Ondansetron doses in lug/kg b.i.d. Placebo (Plac) ndeton 1 g/kg b.i.d. Ondansetron 4 ug/kg Ondansetron 16 g/kg b.i.d. b.i.d. (Ond 4) (Ond 16) FIG. 2A Patent Application Publication Mar. 17, 2011 Sheet 4 of 15 US 2011/0065628A1 Mean CDT Ratio Plac Ond 1 Ond 4 Ond 16 Ondansetron doses in g/kg b.i.d. Placebo (Plac) Ondansetron 1 ug/kg b.i.d. (Ond 4) Ondansetron 4 g/kg H Ondansetron 16 ug/kg b.i.d. b.i.d. (Ond 4) (Ond 16) FIG. 2B Patent Application Publication Mar. 17, 2011 Sheet 5 of 15 US 2011/0065628A1 6 O Group Mean -0- 0. Naltrexone 4O -- 0.3 Naltrexone -0- 1.0 Naltrexone 2O -- 3.0 Naltrexone O -2O AQ S S S S) (S 19 QS QS SS AS S S AS as es 1S AS Time (10 minute time blocks) FIG. 3 Patent Application Publication Mar. 17, 2011 Sheet 6 of 15 US 2011/0065628A1 1O 9 Mean 8 drinks/ 6 drinking 5 day 4 \ 3 2 1 O O 1 2 3 4 5 6 7 8 ? A Study Weeks Baseline Start of double-blind Ondansetron 4 u g/kg b.i.d. + Naltrexone 25 mg b.i.d. group -O-Placebo group FIG. 4A Patent Application Publication Mar. 17, 2011 Sheet 7 of 15 US 2011/0065628A1 12 11 1O Mean 9 drinks/ 8 drinking 7 day 6 5 4 3 2 1. O O l 2 3 4 5 6 7 8 A A Study Weeks Baseline Start of double-blind Ondansetron 4 u g/kg b.i.d. + Naltrexone 25 mg b.i.d. group -O-Placebo group FIG. 4B Patent Application Publication Mar. 17, 2011 Sheet 8 of 15 US 2011/0065628A1 || || || 1 1 2 3 4 5 6 7 8 9 1 0 1 1 12 Week of Study - A - Placebo -O-2.5 mg Rit - a 5.0 mg Rit FIGS Patent Application Publication Mar. 17, 2011 Sheet 9 of 15 US 2011/0065628A1 Alcohol Dependent patients N=360 Early Onset Alcoholics Late Onset Alcoholics (EOA) N=180 (LOA) N=180 •Alcoholism onsets 25 years •Alcoholism onset >25 years •High family history of alcoholism •Less family history of alcoholism in 1st degree relatives in list degree relatives "Antisocial behaviors and symptoms •Few antisocial behaviors and symptoms Cognitive Behavioral Therapy Cognitive Behavioral Therapy Placebo Ondansetron Ondansetron -- Ondansetron Ondansetron Placebo Placebo Naltrexone Placebo Naltrexone Naltrexone Naltrexone Placebo N=45 N=45 N=45 F.G. 6 Patent Application Publication Mar. 17, 2011 Sheet 10 of 15 US 2011/0065628A1 Study years Subject Enrolled Completed Effect of Naltrexone/Topiramate on Alcohol Consumption o E p e Vehicle 5 Top 10 Top Nalf Naf10 Top 1 Nal -24 5 Top FIG. 8 Patent Application Publication Mar. 17, 2011 Sheet 11 of 15 US 2011/0065628A1 Efferents to Frontal Cortex 8 HippocampuS Efferents to Hippocampus 5HT3 receptors 3- endorphins Serotonin 5HT3 receptor facilitated GABA interneurons Dopamine Afferent from the Hippocampus to the N. Accumbens Patent Application Publication Mar. 17, 2011 Sheet 12 of 15 US 2011/0065628A1 7 6 Ethanol intake 5 (-12%) (g/kg) w 3 2 1 2 3 4. 5 6 7 Session FIG 10A Ethanol intake (glkg) Session FIG 10B Patent Application Publication Mar. 17, 2011 Sheet 13 of 15 US 2011/0065628A1 6 (1%) Ethanol 5 W intake (g/kg) 4 3 2 1 2 3 4. 5 6 7 Session FIG 10C 7 6 (17%) Ethanol intake 5 w (g/kg) 3 2 1 2 3 4. 5 6 7 Session FIG 10D Patent Application Publication Mar. 17, 2011 Sheet 14 of 15 US 2011/0065628A1 7 6 Ethanol 5 - intake (g/kg)Ik 4. - (28%) 3 - W Session FIG 10E Patent Application Publication Mar. 17, 2011 Sheet 15 of 15 US 2011/0065628A1 Prefrontal cortex Arnygdala GLU Serotonin Lateral septum Cholinergic Modulatory Input Hippocampus. Excitatory input From Raphe. Nuclei From PPTg and LDT.g | ExcitatoryGU Input CB1R Enkephalin Dopamine inhibitory input (D1, D2, D3) From Nucleus Ya GABA Arcuatus Inhibitory Input Neuron h GABA Neuron 5-HT3-R Receptors Mu a 3 GABA inhibitory Feedback N GABA Neuron REINFORCEENT Wentral Tegmental Area H (WTA) — H Nucleus(nACC) Accumbens — FIG 11 US 2011/0065628 A1 Mar. 17, 2011 MEDICATION COMBINATIONS FOR THE targeted towards correcting or ameliorating the underlying TREATMENT OF ALCOHOLISMAND DRUG abnormalities. Because these abnormalities involve several ADDICTION neurotransmitters, combinations of medications targeting specific systems may yield better clinical outcomes than CROSS REFERENCE TO RELATED treatment of only one affected pathway would alone. Hence, APPLICATIONS obtaining optimal treatment matching combinations for vari 0001. This application is entitled to priority pursuant to 35 ous types of alcoholic remains an important research goal. U.S.C. S 119(e) to U.S. provisional patent application No. 0006 Alcohol abuse and dependence are widespread and 60/966,265, filed on Aug. 27, 2007. The entire disclosure of it is estimated that 14 million American adults abused alcohol the afore-mentioned patent application is incorporated herein or were dependent on it in 1992 and that approximately 10% by reference. of Americans will be affected by alcohol dependence some time during their lives. Alcohol dependence, characterized by STATEMENT REGARDING FEDERALLY the preoccupation with alcohol use, tolerance, and with SPONSORED RESEARCH ORDEVELOPMENT drawal, is a chronic disorder with genetic, psychosocial, and environmental factors influencing its development and mani 0002 This invention was made in part with United States festations. Studies have demonstrated the significance of Government support under National Institutes of Health opioids (i.e., beta-endorphin), dopamine (DA), serotonin Grant Nos. AAO12964 and AA13074. The United States Gov (5-HT), Y-amino-butyric acid (GABA), and glutamate for the ernment has certain rights in the invention. development and maintenance of alcohol dependence. To date, most pharmacotherapy trials have focused on single FIELD OF THE INVENTION pharmacological agents. However, because of the failure to 0003. The present invention relates generally to the use of find consistent results with these drug therapies, investigating combination therapies to treat addiction-related diseases and the efficacy of combining drugs that target multiple neu disorders and impulse control disorders, particularly alcohol rotransmitter systems or genes is perhaps more important to related diseases and disorders. the development of future pharmacotherapies for treatment of alcohol dependence and treatment of other addictive disor BACKGROUND ders and impulse control disorders. 0004 Neuroscientific advances have greatly increased the 0007 Various medications and behavioral therapy have understanding of the pharmaco-behavioral effects of various been used to treat alcohol dependence. The neuronal targets neurotransmitter systems in the acquisition and maintenance of alcohol include many neurotransmitter systems and the of alcohol dependence. Medications that interact either molecules participating in or regulating the systems, includ directly or indirectly with neurotransmitters that modulate ing GABA, glutamate, DA, opioids, and serotonin (for a cortico-mesolimbic dopamine (CMDA) neurons have been review see Johnson, 2004, Expert Opin. Pharmacother. 5:9: central to most pharmacological strategies in the last decade 1943-1955).
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Curriculum Vitae April 2013

    Curriculum Vitae April 2013

    Curriculum Vitae April 2013 NAME Michael Jeffrey Aminoff CONTACT Box 0114, Room 795-M, Dept of Neurology, 505 Parnassus Ave., San Francisco, CA 94143-0114 Tel: 415 353-1940; Fax 415 353-3289 [email protected] PLACE OF BIRTH England NATIONALITY British and US MARITAL STATUS Married, with three children CURRENT TITLE Endowed Chair in Parkinson’s Disease Research Distinguished Professor of Neurology & Executive Vice Chair, Department of Neurology, School of Medicine University of California, San Francisco Attending Physician (Neurologist) University of California Medical Center, San Francisco Director, Parkinson's Disease & Movement Disorders Clinic University of California Medical Center, San Francisco EDUCATION AND TRAINING EARLY EDUCATION Caterham School, Surrey, England MEDICAL SCHOOL University College, London, England, 1959-1962 University College Hospital, England, 1962-1965 QUALIFICATIONS 1962 B.Sc. Special (London) 1965 L.R.C.P., M.R.C.S., M.B., B.S. [Equivalent to MD degree in USA] 1968 M.R.C.P. (London) [Similar to Board Certification in Internal Medicine in USA] 1973 M.D. (London) [Advanced Research Thesis similar to Ph.D. in USA] 1976 Federal Licensing Examination and California Medical License 1977 Membership by examination, American Association of Electromyography & Electrodiagnosis, leading in 1989 to Certification by American Board of Electrodiagnostic Medicine. 1980 Certification by the American Board of Clinical Neurophysiology (ABQEEG) 1982 Certification in Neurology, American Board of Psychiatry & Neurology; recertified voluntarily, 2004 1984 F.R.C.P. (London) 1992 Subspecialty certification in Clinical Neurophysiology, American Board of Psychiatry & Neurology (new subspecialty); recertified 2002 1 2000 D.Sc. (London) [Higher doctorate in Faculty of Science, London University, London, UK] PRINCIPAL POSITIONS HELD 1965-1966 House physician & house surgeon, University College Hospital, London, U.K.
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al

    (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al

    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al

    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
  • Effects of Some Agents on Receptor-And Cell Volume-Controlled

    Effects of Some Agents on Receptor-And Cell Volume-Controlled

    EFFECTS OF SOME AGENTS ON RECEPTOR- AND CELL VOLUME- CONTROLLED CHANGES IN THE IONIC PERMEABILITY OF ISOLATED GUINEA-PIG HEPATOCYTES Christine A. Sandford A thesis submitted for the degree of Doctor of Phiiosophy. Department of Pharmacology University College London Gower Street LONDON WC1E 6BT 1992 ProQuest Number: 10017717 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10017717 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Sodium-linked amino acid transport causes an increase in the membrane permeability of liver cells to potassium. This effect on permeability is generally attributed to the concomitant rise in cell volume produced by the inward movement of solute. It is thought to form the basis of the subsequent regulatory volume decrease. The first part of this study examined the pharmacology and electrical characteristics of cell volume regulation In isolated guinea-pig hepatocytes using intracellular recording techniques and the whole cell variant of the patch clamp technique. In patch clamp studies, cell swelling was induced by the application of hydrostatic pressure to the shank of the patch pipette.
  • Information to Users

    Information to Users

    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. U M I films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send U M I a complete manuscript and there are missing pages, these w ill be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact U M I directly to order. University Microfilms International A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor, Ml 48106-1346 USA 313/761-4700 800/521-0600 Order Number 9427799 Part 1: Design, synthesis and biological activities2-(4 of -isothiocyanatobenzyl)imidazoline analogues in rat and bovine tissues.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.